علاج جدري القردة لدى المرضى الحوامل أو المرضعات

References

1. It may need to be used when the safety of Tecovirimat has not been established such as during pregnancy and breastfeeding.
2. Persons who are pregnant or breastfeeding (see VIG under Treatment Options).
3. VIG is held in the NMS in limited quantities. It may need to be used when the safety of Tecovirimat has not been established such as during pregnancy and breastfeeding.
4. Dose of 6000 Units/kg intravenous.
5. Consider higher doses where the patient does not respond to the initial dose. Multiple and repeated treatments may be required.
6. Bring VIG vials to room temperature prior to dosing. Administer 6000 U/kg intravenously through a dedicated intravenous line with the infusion rate of no greater than 2 mL/min.